Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer
References (52)
- et al.
Angiogenesis
J. Biol. Chem.
(1992) - et al.
Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study
Eur. J. Cancer Clin. Oncol.
(1986) - et al.
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma
Cell
(1994) - et al.
Vascular permeability factor mRNA and protein expression in human kidney
Kidney Int.
(1992) - et al.
Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma
Cancer Lett.
(1996) - et al.
Assessment of angiogenesis in breast carcinoma: an important factor in prognosis?
Hum. Pathol.
(1995) - et al.
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
Hum. Pathol.
(1995) - et al.
Identitication of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor
Biochem. Biophys. Res. Commun.
(1992) - et al.
Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells
J. Invest. Dermatol.
(1995) - et al.
Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma
N. Engl. J. Med.
(1991)
Microvessel count predicts metastatic disease and survival in non-small cell lung cancer
J. Pathol.
Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas
Cancer Res.
Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor secreted products
J. Immunol.
Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract
Lab. Invest.
Angiogenic factor
Nature
Scatter factor induces blood vessel formation in vivo
Expression of transforming growth factor alpha messenger RNA in the normal and neoplastic gastrointestinal tract
Int. J. Cancer
Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells
Am. J. Pathol.
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
Science
Angiogenesis: initiation and modulation
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
Am. J. Pathol.
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Nature
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
J. Clin. Invest.
Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma
J. Clin. Oncol.
Tumor angiogenesis and mode of metastasis in patients with colorectal cancer
Cancer Res.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer
Int. J. Cancer
Cited by (94)
Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma
2020, European Journal of Medicinal ChemistryCitation Excerpt :These VEGFRs reside on the exterior of vascular endothelial cells, lymph vessels, and hematopoietic stem cells [5]. Among three VEGFRs, overexpression of VEGFR-2 is prominent in the various cancers, viz. HCC, RCC, NSCLC, TNBC, breast cancer, bladder cancer, and cervical cancer, thus VEGFR-2 is a recognized target for the discovery of anti-angiogenic agents to prevent tumor progression [6–12]. There are three types of VEGFR-2 inhibitors: ATP competitive inhibitors (type I), allosteric inhibitors (type II), and covalent inhibitors (type III) [13].
Review on TAS-102 development and its use for metastatic colorectal cancer
2016, Critical Reviews in Oncology/HematologyCitation Excerpt :Later, they were identified as having the same protein structure and biological functions (Moghaddam and Bicknell, 1992; Moghaddam et al., 1995). PD-ECGF/TP increases endothelial cell migration and neovascular sprouting (Moghaddam et al., 1995; Hotchkiss et al., 2003) and may provide a VEGF-alternative mechanism for neovascularization, since tumors exhibiting high blood vessel density in conjunction with low VEGF expression often present high levels of PD-ECGF/TP (Amaya et al., 1997). PD-ECGF/TP is commonly overexpressed in colorectal cancer cells (van Triest et al., 2000) and in elements of the tumor microenvironment, such as the tumor-associated macrophages (Takahashi et al., 1996).
Is VEGF a predictive biomarker to anti-angiogenic therapy?
2011, Critical Reviews in Oncology/HematologyCitation Excerpt :These different findings about the correlation of VEGF with prognosis make it difficult to draw definitive conclusions as to the prognostic value of VEGF measurement whether in tumor or in serum. Several studies have found that increased VEGF expression is associated with tumor progression [23,25,33] and VEGF has also been shown to correlate with the extent of tumor vascularization in many studies [24,33,35]. Some studies have evaluated whether VEGF receptor expression correlates with prognosis.
Thymidine Phosphorylase Expression in Human Bladder Urothelial Carcinoma
2011, Urological ScienceNew antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization
2023, Molecular DiversityExploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, ‘DFG-out’ inhibitors
2022, Journal of Biomolecular Structure and Dynamics